4,680
Participants
Start Date
March 29, 2018
Primary Completion Date
March 15, 2020
Study Completion Date
March 15, 2020
dihydroartemisinin-piperaquine
Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin placebo
sulphadoxine-pyrimethamine
Women randomised to this intervention will receive stat dose of 3 tablets of 500 mg sulphadoxine and 25 mg of pyrimethamine each (total dose of 1,500mg sulphadoxine and 75mg pyrimethamine) on a single day of clinic visit
dihydroartemisinin-piperaquine plus azithromycin
Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin (500mg)
Ahero Sud-countyHospital, Ahero
Homa Bay County Hospital, Homa Bay
Rabour Sub-county Hospital, Kisumu
Chikwawa District Hospital, Chikwawa
Mangochi District Hospital, Mangochi
Handeni District Hospital, Handeni
Korogwe District Hospital, Korogwe
Collaborators (1)
Kamuzu University of Health Sciences
OTHER
Kenya Medical Research Institute
OTHER
Malawi-Liverpool-Wellcome Trust Clinical Research Programme
OTHER
National Institute for Medical Research, Tanzania
OTHER_GOV
Kilimanjaro Christian Medical Centre, Tanzania
OTHER
University of Copenhagen
OTHER
Centers for Disease Control and Prevention
FED
London School of Hygiene and Tropical Medicine
OTHER
University College, London
OTHER
Tampere University
OTHER
University of Bergen
OTHER
University of Massachusetts, Worcester
OTHER
University of Toronto
OTHER
University of Melbourne
OTHER
Foundation for Innovative New Diagnostics, Switzerland
OTHER
Liverpool School of Tropical Medicine
OTHER